TScan Therapeutics (TCRX) Non-Current Debt (2022 - 2026)
TScan Therapeutics (TCRX) posted quarterly Non-Current Debt of $32.7 million for Q1 2026, up 1.47% year-over-year from $32.2 million in Q1 2025, and little changed quarter-over-quarter from $32.5 million in Q4 2025.
TScan Therapeutics (TCRX) Non-Current Debt (2022 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Non-Current Debt for 5 consecutive years, with $32.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 1.47% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at $32.7 million (up 1.47% YoY), while the FY2025 annual figure was $32.5 million, up 1.44% from the prior year.
- Non-Current Debt was little changed at $32.7 million in Q1 2026 per TCRX's latest filing, from $32.5 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $32.7 million in Q1 2026 and bottomed at $20.1 million in Q2 2024.
- Historically, Non-Current Debt has averaged $29.4 million across 5 years, with a median of $29.7 million in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Debt tumbled 32.33% — and 2025, when it soared 60.58%.
- TScan Therapeutics' Non-Current Debt stood at $29.3 million in 2022, then retreated by 8.84% to $26.7 million in 2023, then grew by 20.12% to $32.1 million in 2024, then increased by 1.44% to $32.5 million in 2025, then increased by 0.37% to $32.7 million in 2026.
- Business Quant data shows TCRX's Non-Current Debt at $32.7 million in Q1 2026, $32.5 million in Q4 2025, and $32.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 21.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.07 Mn |
| Mar 31, 2026 | 32.65 Mn |
| Dec 31, 2025 | 32.53 Mn |
| Sep 30, 2025 | 32.41 Mn |
| Jun 30, 2025 | 32.30 Mn |
| Mar 31, 2025 | 32.18 Mn |
| Dec 31, 2024 | 32.07 Mn |
| Sep 30, 2024 | 30.65 Mn |
| Jun 30, 2024 | 20.11 Mn |
| Mar 31, 2024 | 23.45 Mn |
| Dec 31, 2023 | 26.70 Mn |
| Sep 30, 2023 | 28.84 Mn |
| Jun 30, 2023 | 29.72 Mn |
| Mar 31, 2023 | 29.50 Mn |
| Dec 31, 2022 | 29.29 Mn |
| Sep 30, 2022 | 29.07 Mn |